Omnicell (NASDAQ:OMCL) Price Target Lowered to $145.00 at Piper Sandler

Omnicell (NASDAQ:OMCLGet Rating) had its price objective lowered by Piper Sandler from $150.00 to $145.00 in a research report released on Wednesday morning, The Fly reports. The brokerage currently has an overweight rating on the stock.

Several other analysts have also commented on OMCL. SVB Leerink began coverage on Omnicell in a report on Friday, July 15th. They set a market perform rating and a $124.00 target price on the stock. Bank of America initiated coverage on Omnicell in a report on Friday, September 9th. They set a buy rating and a $120.00 target price on the stock. BTIG Research lowered their price target on Omnicell from $190.00 to $175.00 and set a buy rating on the stock in a research report on Wednesday, July 27th. Finally, KeyCorp initiated coverage on Omnicell in a research report on Thursday, September 15th. They set an overweight rating and a $130.00 price target on the stock. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Omnicell currently has an average rating of Moderate Buy and a consensus price target of $148.86.

Omnicell Stock Up 1.0 %

Shares of OMCL stock opened at $90.82 on Wednesday. The firm has a market capitalization of $4.02 billion, a PE ratio of 72.08, a P/E/G ratio of 2.69 and a beta of 1.06. Omnicell has a fifty-two week low of $88.44 and a fifty-two week high of $187.29. The stock’s 50-day simple moving average is $105.93 and its 200-day simple moving average is $114.36. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.71 and a current ratio of 2.11.

Omnicell (NASDAQ:OMCLGet Rating) last posted its earnings results on Thursday, August 4th. The company reported $0.84 EPS for the quarter, missing the consensus estimate of $0.85 by ($0.01). The company had revenue of $331.39 million for the quarter, compared to analyst estimates of $339.45 million. Omnicell had a return on equity of 10.37% and a net margin of 4.82%. The firm’s revenue was up 21.5% on a year-over-year basis. During the same period last year, the business earned $0.71 earnings per share. Equities analysts expect that Omnicell will post 2.6 earnings per share for the current year.

Insider Activity

In other news, CEO Randall A. Lipps sold 13,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 16th. The stock was sold at an average price of $111.04, for a total value of $1,443,520.00. Following the transaction, the chief executive officer now owns 302,049 shares in the company, valued at $33,539,520.96. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CFO Peter J. Kuipers sold 11,000 shares of the firm’s stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $105.93, for a total value of $1,165,230.00. Following the transaction, the chief financial officer now owns 61,326 shares in the company, valued at $6,496,263.18. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Randall A. Lipps sold 13,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $111.04, for a total value of $1,443,520.00. Following the completion of the transaction, the chief executive officer now owns 302,049 shares in the company, valued at approximately $33,539,520.96. The disclosure for this sale can be found here. Insiders have sold a total of 39,500 shares of company stock worth $4,287,245 over the last quarter. 2.76% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Omnicell

Hedge funds and other institutional investors have recently made changes to their positions in the company. Synovus Financial Corp increased its holdings in shares of Omnicell by 0.5% in the fourth quarter. Synovus Financial Corp now owns 15,312 shares of the company’s stock valued at $2,760,000 after purchasing an additional 77 shares during the last quarter. CWM LLC increased its holdings in shares of Omnicell by 16.9% in the second quarter. CWM LLC now owns 637 shares of the company’s stock valued at $72,000 after purchasing an additional 92 shares during the last quarter. Louisiana State Employees Retirement System increased its holdings in shares of Omnicell by 0.5% in the first quarter. Louisiana State Employees Retirement System now owns 21,400 shares of the company’s stock valued at $2,567,000 after purchasing an additional 100 shares during the last quarter. Archer Investment Corp increased its holdings in shares of Omnicell by 27.1% in the second quarter. Archer Investment Corp now owns 469 shares of the company’s stock valued at $53,000 after purchasing an additional 100 shares during the last quarter. Finally, Maryland State Retirement & Pension System increased its holdings in shares of Omnicell by 0.6% in the first quarter. Maryland State Retirement & Pension System now owns 17,621 shares of the company’s stock valued at $2,282,000 after purchasing an additional 103 shares during the last quarter.

About Omnicell

(Get Rating)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Read More

The Fly logo

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.